Quantcast
Last updated on April 18, 2014 at 15:29 EDT

Latest Non-steroidal anti-inflammatory drugs Stories

2012-07-23 23:00:41

For the nearly 70 million United States residents who suffer with some type of Joint pain, the search for a cure for this ailment or at least some sort of constant relief is a primary concern. Recent discoveries of new-age remedies, medical research as well as a great article posted at Health and Wellness portal BeWellBuzz.com has brought forth cautious optimism that new forms of relief could be on the horizon for nearly one-third of the US population who deal with joint pain on a daily...

2012-07-23 02:25:18

MISSISSAUGA, ON, July 23, 2012 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain, today is providing an update on the status of its PENNSAID franchise. PENNSAID (diclofenac sodium topical solution) 1.5% w/w U.S. Patent The United States Patent Office has issued Patent # 8,217,078 relating to a method of using PENNSAID (PENNSAID Patent).  The PENNSAID Patent expiry...

2012-07-17 02:27:16

DENVER, July 17, 2012 /PRNewswire/ -- Big Pharma didn't invent aspirin. Mother Nature did. "Today, most people think of aspirin as a harmless wonder drug -- able to stop pain, fever and even prevent heart attack and stroke, without risk. But that's not true," said The People's Chemist, Shane Ellison, who holds a M.S. degree in organic chemistry and is author of "Over-The-Counter Natural Cures" book. "Thousands of years ago, humans witnessed injured bears gnawing on the bark of white willow...

2012-07-06 10:21:53

MENLO PARK, Calif., July 6, 2012 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the JMP Securities 7th Annual Healthcare Conference in New York City. The presentation at the JMP conference is scheduled for 10:00 am EDT (7:00 am PDT) on Friday, July 13. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcast will be archived for 30 days...

2012-06-25 02:26:10

SHIRLEY, N.Y., June 25, 2012 /PRNewswire/ -- Regency Therapeutics, a division of Luitpold Pharmaceuticals, Inc., announced today that a national registry has been launched by a group of academic emergency medicine specialists led by Charles Pollack, MA, MD, FAAEM, FACEP, FAHA, Professor and Chairman, Department of Emergency Medicine, Pennsylvania Hospital, University of Pennsylvania Health System. The purpose of the registry is to evaluate patient experience with...

2012-06-21 10:26:40

MENLO PARK, Calif., June 21, 2012 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) today announced that it has acquired all rights to Zipsor(®) (diclofenac potassium) Liquid Filled Capsules from Xanodyne Pharmaceuticals, Inc. Zipsor is a non-steroidal anti-inflammatory drug (NSAID) indicated for relief of mild to moderate acute pain in adults. The product uses proprietary ProSorb(®) delivery technology to deliver a finely dispersed, rapidly absorbed formulation of diclofenac. Zipsor,...

2012-06-19 02:27:28

DEERFIELD, Ill., June 19, 2012 /PRNewswire/ -- Horizon Pharma, Inc. (NASDAQ: HZNP) a biopharmaceutical company developing and commercializing innovative medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases, today announced that it entered into an exclusive agreement with Grunenthal for the commercialization of DUEXIS in Latin America. "As this is our first out-license of DUEXIS outside the United States, we are especially pleased to partner in Latin...

2012-06-18 02:26:29

DEERFIELD, Ill., June 18, 2012 /PRNewswire/ -- Horizon Pharma, Inc. (NASDAQ: HZNP) and Mallinckrodt LLC the Pharmaceuticals business of Covidien (NYSE: COV), announced today that they have entered into a U.S. co-promotion agreement for DUEXIS® (ibuprofen and famotidine), which is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers. "This collaboration with Mallinckrodt will expand...

2012-06-14 02:24:41

-- U.S. licensee resumes distribution of PENNSAID sample bottles MISSISSAUGA, ON, June 14, 2012 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain, today announced that its U.S. marketing partner, Mallinckrodt Inc., the Pharmaceuticals business of Covidien, has advised Nuvo that it has resumed distribution of 15 mL sample bottles of PENNSAID(®) (diclofenac...

2012-06-11 11:41:23

Aspirin taken for five days before a heart operation can halve the numbers of patients developing post-operative acute kidney failure, according to research presented at the European Anaesthesiology Congress in Paris today (Sunday). Professor Jianzhong Sun (MD, PhD), professor and attending anesthesiologist at Jefferson Medical College, Thomas Jefferson University (Philadelphia, USA), told the meeting that in a study of 3,219 patients, pre-operative aspirin therapy was associated with a...